CHCarl He

Carl He

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Carl He has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Unresectable Primary Enteric‐Type Thymic Adenocarcinoma Treated With FOLFOX Chemotherapy: A Case Report

    by Carl He, Georgia Bentick, Patrick Hosking, Andrew Mant

    Background: Enteric‐type thymic adenocarcinomas are an extremely rare and distinct subtype of thymic malignancies, as classified by the 2021 World Health Organization classification of thymic tumors. These tumors exhibit close molecular and morphologic similarity to primary gastrointestinal malignancies. To date, there are no tailored treatment guidelines for enteric‐type thymic adenocarcinoma.Case: A 65‐year‐old woman was admitted to the Oncology unit of a Melbourne Metropolitan Hospital after presenting with progressive symptoms of thoracic outlet syndrome, where a CT scan identified a localized anterior mediastinal mass measuring up to 7.5 × 6.0 × 6.0 cm (transverse × Anterior–Posterior × Superior–inferior). The mass was deemed unresectable. A core biopsy diagnosed the patient with a primary enteric‐type thymic adenocarcinoma, based on positive immunohistochemical staining for the intestinal markers CK20 and CDX2, positive staining for CD5—a marker commonly associated with thymic carcinoma, and positive staining for CK7—a marker not classically expressed in colonic adenocarcinoma. The patient received five fractions of 20 Gray palliative radiotherapy for superior vena cava syndrome, followed by four cycles of Oxaliplatin/5‐fluorouracil/leucovorin (FOLFOX) chemotherapy. FOLFOX, a common systemic therapy for gastrointestinal adenocarcinomas, was chosen due to the tumor's enteric profile and was selected over the then‐NCCN‐recommended carboplatin/paclitaxel regimen, which did not have trial‐backed evidence of efficacy in thymic adenocarcinomas, particularly adenocarcinomas of the enteric type. After starting on frontline systemic therapy with FOLFOX, restaging scans after Cycle 3 showed a reduction in the size of her anterior mediastinal mass, which further decreased in size after cycle 4. Treatment was then discontinued per the patient's goals of care; however, follow‐up imaging showed ongoing disease stability for 6 months. The patient died of disease 8 months after treatment discontinuation and 13 months after her initial diagnosis.Conclusion: We report the first case of primary enteric‐type thymic adenocarcinoma treated at an Australian institution, and the first published case using FOLFOX as frontline systemic therapy in a patient with unresectable primary enteric‐type thymic adenocarcinoma. Noting the close molecular resemblance between enteric‐type thymic adenocarcinoma and gastrointestinal malignancies, chemotherapy regimens commonly used in the treatment of gastrointestinal cancer may offer a more effective option than standard frontline therapies used in thymic carcinomas for the management of enteric‐type thymic adenocarcinoma.


  • Open Access

    Activating Invasion and Metastasis in Small Cell Lung Cancer: Role of the Tumour Immune Microenvironment and Mechanisms of Vasculogenesis, Epithelial‐Mesenchymal Transition, Cell Migration, and Organ Tropism

    by Carl He

    Background: Small cell lung cancer (SCLC) harbours the most aggressive phenotype of all lung cancers to correlate with its bleak prognosis. The aggression of SCLC is partially attributable to its strong metastatic tendencies. The biological processes facilitating the metastasis in SCLC are still poorly understood and garnering a deeper understanding of these processes may enable the exploration of additional targets against this cancer hallmark in the treatment of SCLC.Recent Findings: This narrative review will discuss the proposed molecular mechanisms by which the cancer hallmark of activating invasion and metastasis is featured in SCLC through important steps of the metastatic pathway, and address the various molecular targets that may be considered for therapeutic intervention. The tumour immune microenvironment plays an important role in facilitating immunotherapy resistance, whilst the poor infiltration of natural killer cells in particular fosters a pro‐metastatic environment in SCLC. SCLC vasculogenesis is achieved through VEGF expression and vascular mimicry, and epithelial‐mesenchymal transition is facilitated by the expression of the transcriptional repressors of E‐cadherin, the suppression of the Notch signalling pathway and tumour heterogeneity. Nuclear factor I/B, selectin and B1 integrin hold important roles in SCLC migration, whilst various molecular markers are expressed by SCLC to assist organ‐specific homing during metastasis. The review will also discuss a recent article observing miR‐1 mRNA upregulation as a potential therapeutic option in targeting the metastatic activity of SCLC.Conclusion: Treatment of SCLC remains a clinical challenge due to its recalcitrant and aggressive nature. Amongst the many hallmarks used by SCLC to enable its aggressive behaviour, that of its ability to invade surrounding tissue and metastasise is particularly notable and understanding the molecular mechanisms in SCLC metastasis can identify therapeutic targets to attenuate SCLC aggression and improve mortality.


  • Open Access

    Manuscript title: Activating invasion and metastasis in small cell lung cancer

    by Carl He

    Background: Small cell lung cancer (SCLC) harbours the most aggressive phenotype of all lung cancers to correlate with its bleak prognosis. The aggression of SCLC is partially attributable to its strong metastatic tendencies. The biological processes facilitating the metastasis in SCLC are still poorly understood and garnering a deeper understanding of these processes may enable the exploration of additional targets against this cancer hallmark in the treatment of SCLC. Recent findings: This narrative review will discuss the proposed molecular mechanisms by which the cancer hallmark of activating invasion and metastasis is featured in SCLC through important steps of the metastatic pathway. The review will discuss SCLC VEGF family expression and vascular mimicry as a means of vasculogenesis, and the role of tumour heterogeneity, DLL3, NFIB, selectin, and B1 integrin in enabling epithelial to mesenchymal transition and subsequent invasion, and the molecular markers expressed by SCLC to assist organ-specific homing during metastasis. The review will also discuss a recent article observing mir-1 mrna upregulation as a potential therapeutic option in targeting the metastatic activity of SCLC. Conclusion: Treatment of SCLC remains a clinical challenge due to its recalcitrant and aggressive nature. Amongst the many hallmarks used by SCLC to enable its aggressive behaviour, that of its ability to invade surrounding tissue and metastasise is particularly notable and understanding the molecular mechanisms in SCLC metastasis can identify therapeutic targets to attenuate SCLC aggression and improve mortality.

  • Efficacy of sacral neuromodulation and percutaneous tibial nerve stimulation in the treatment of chronic nonobstructive urinary retention: A systematic review

    by Felicia Ching Siew Ho, Carl He, Henry Han‐I Yao, Helen E. O'COnnell, Johan Gani

    Aim: The aim of this systematic review is to provide an updated report on the efficacy and complications of sacral neuromodulation (SNM) and percutaneous tibial nerve stimulation (PTNS) in the treatment of chronic nonobstructive urinary retention (CNOUR), with a focus on the contemporary technique of SNM utilizing the percutaneous placement of tined leads.Methods: This systematic review was conducted with the use of PRISMA guidelines and registered with PROSPERO (CRD42020208052). A systematic literature search was conducted in Embase, PubMed, and Cochrane databases. Inclusion criteria include English language and human participants. Exclusion criteria include SNM studies involving less than 10 CNOUR patients, studies containing data obtained using open, surgical implantation of nontined leads, and studies that only reported the test phase success rate with no long‐term efficacy data. The risk of bias assessment was conducted using the National Institutes of Health study quality assessment tool.Results: A total of 16 papers studies were included (11 SNM and 5 PTNS) in this review. The success rate for SNM ranges between 42.5% and 100% (median = 79.2%) for the test stimulation phase and 65.5%–100% (median = 89.1%) in the long term. Most SNM studies reported revision and explantation rates of lesser than 20%. The success rate was much lower for PTNS, in the 50%–60% range and complications were minimal.Conclusion: SNM using the contemporary percutaneous tined lead implantation technique appears to be an effective treatment for CNOUR and is durable in the long term. Compared to SNM, PTNS appears less efficacious with less evidence supporting its use in CNOUR. Further prospective studies are required to define the role of PTNS in the treatment of CNOUR.